These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24721645)

  • 1. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab.
    Saenger Y; Magidson J; Liaw B; de Moll E; Harcharik S; Fu Y; Wassmann K; Fisher D; Kirkwood J; Oh WK; Friedlander P
    Clin Cancer Res; 2014 Jun; 20(12):3310-8. PubMed ID: 24721645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
    Friedlander P; Wassmann K; Christenfeld AM; Fisher D; Kyi C; Kirkwood JM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2017 Aug; 5(1):67. PubMed ID: 28807052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
    Friedlander P; Wood K; Wassmann K; Christenfeld AM; Bhardwaj N; Oh WK
    J Immunother Cancer; 2018 Sep; 6(1):90. PubMed ID: 30227886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
    Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
    Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
    Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
    Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
    Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
    Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
    J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
    Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
    Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.
    Lotem M; Merims S; Frank S; Hamburger T; Nissan A; Kadouri L; Cohen J; Straussman R; Eisenberg G; Frankenburg S; Carmon E; Alaiyan B; Shneibaum S; Ozge Ayyildiz Z; Isbilen M; Mert Senses K; Ron I; Steinberg H; Smith Y; Shiloni E; Gure AO; Peretz T
    J Immunol Res; 2016; 2016():8121985. PubMed ID: 27294163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
    Kantoff PW; Halabi S; Farmer DA; Hayes DF; Vogelzang NA; Small EJ
    J Clin Oncol; 2001 Jun; 19(12):3025-8. PubMed ID: 11408497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
    Wang E; Kang D; Bae KS; Marshall MA; Pavlov D; Parivar K
    J Clin Pharmacol; 2014 Oct; 54(10):1108-16. PubMed ID: 24737343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of osteopontin expression in melanoma progression.
    Kiss T; Ecsedi S; Vizkeleti L; Koroknai V; Emri G; Kovács N; Adany R; Balazs M
    Tumour Biol; 2015 Sep; 36(10):7841-7. PubMed ID: 25944164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy.
    Felix J; Cassinat B; Porcher R; Schlageter MH; Maubec E; Pages C; Baroudjian B; Homyrda L; Boukouaci W; Tamouza R; Bagot M; Caignard A; Toubert A; Lebbé C; Moins-Teisserenc H
    Int Immunopharmacol; 2016 Nov; 40():466-473. PubMed ID: 27728898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
    Ribas A
    Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
    Brüggemann C; Kirchberger MC; Goldinger SM; Weide B; Konrad A; Erdmann M; Schadendorf D; Croner RS; Krähenbühl L; Kähler KC; Hafner C; Leisgang W; Kiesewetter F; Dummer R; Schuler G; Stürzl M; Heinzerling L
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):1977-1984. PubMed ID: 28616701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
    Reuben JM; Lee BN; Li C; Gomez-Navarro J; Bozon VA; Parker CA; Hernandez IM; Gutierrez C; Lopez-Berestein G; Camacho LH
    Cancer; 2006 Jun; 106(11):2437-44. PubMed ID: 16615096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting clinical outcome through molecular profiling in stage III melanoma.
    John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS
    Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients.
    Brunner G; Reitz M; Schwipper V; Tilkorn H; Lippold A; Biess B; Suter L; Atzpodien J
    Cancer Biother Radiopharm; 2008 Aug; 23(4):451-9. PubMed ID: 18771349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.